
    
      At the end of the study, it will propose to continue the usual quarterly patient follow up,
      as recommended by the French ALS centers.

      Deferiprone can be administered as part of a compassionate use, for patients who want it and
      who do not have hypoxemia.

      We therefore plan a treatment period compassionate relatively short and less than 3 years.
    
  